-
The National Drug Supervision and Administration Work Conference was held in Beijing
Time of Update: 2023-02-03
On January 5, the National Drug Supervision and Administration Work Conference was held in Beijing. The meeting was guided by the thought of socialism with Chinese characteristics in the new era, dee
-
In 2023, favorable policies will continue to increase the weight of traditional Chinese medicine, and the long-term opportunities of the sector will be optimistic by institutions
Time of Update: 2023-02-03
On the trading day of the New Year in 2023, the traditional Chinese medicine sector changed in early trading, and in the morning of January 3, Fangsheng Pharmaceutical and Zhongsheng Pharmaceutical touched the limit of increase, and individual stocks such as Kangbei, Hongri Pharmaceutical, and Kunming Pharmaceutical followed suit.
-
The ophthalmic treatment market has reached 210 billion yuan, and the track has ushered in nugget fever
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];The eye is a very important organ for humans, and as eye health becomes more and more important, the size of the ophthalmic medical market has begun to show a steady growth trend.
-
The State Food and Drug Administration released the 63rd batch of generic drug reference preparations
Time of Update: 2023-02-01
After the review and determination of the Expert Committee for the Consistency Evaluation of the Quality and Efficacy of Generic Drugs of the State Medical Products Administration, the list of refere
-
Guangshengtang anti-new coronavirus oral small molecule class of innovative drugs Taizhongding completed and obtained the clinical study (IIT) summary report initiated by the investigator
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];In order to evaluate the efficacy and safety of GST-HG171 (proposed Chinese generic name "Taiatevir") combined with ritonavir (collectively referred to as "Taizhongding") in patients with the new crown of Fujian Guangsheng Zhonglin Biotechnology Co.
-
Regarding matters related to the establishment of Shijiazhuang Air Port as a port for the import of medicines
Time of Update: 2023-01-05
Provincial Institute of DrugMedical Device Annex: Shijiazhuang Market Supervision Administration's special seal for drug import filing General Office of the General Administration of Customs of the State Food and Drug Administration November 15, 2022
-
K drugs, O drugs look down on "medical insurance life and death", 200 billion PD-1 market, who spends
Time of Update: 2022-11-26
The roll does not win, lying and lying uneven. This may be the heart of many PD-1 companies. The roll does not win, lying and lying uneven. This may be the heart of many PD-1 companies. For PD-1, in o
-
Roche "denounces" stone medicine behind: a battle of interests under drug patents
Time of Update: 2022-10-31
On October 18, Roche Pharmaceuticals announced on its official WeChat public account that its innovative drug mabaloxavir tablets (trade name: Sofuda ®) was approved for marketing in China in April 2021, and the drugs and active ingredients are protected by relevant Chinese invention patents.
-
Over 1 billion contrast agents
Time of Update: 2022-05-22
com, the sales of terminal iopromide injection in Chinese public medical institutions will exceed 1 billion yuan in 2020, and the first half of 2021 will increase by more than 20% year-on-year .
-
In order to ensure the quality and safety of drugs, the upgrading and innovation of testing equipment need to be accelerated
Time of Update: 2022-01-27
Pharmaceutical equipment At present, with the continuous development of technology, these instruments used to detect impurities are playing an increasingly important role in the quality control of drugs.
-
Tasly’s wholly-owned subsidiary, Memantine Hydrochloride Sustained-Release Capsules Obtained Drug Registration Certificate
Time of Update: 2022-01-11
On December 21, Tasly issued an announcement stating that its wholly-owned subsidiary, Diyi Pharmaceutical, had issued the Drug Registration Certificate for Memantine Hydrochloride Sustained Release Capsules approved and issued by the National Medical Products Administration for the treatment of moderate to severe Alzheimer’s.
-
Domestic pharmaceutical equipment companies, diversified layout becomes a trend
Time of Update: 2022-01-09
From an overall point of view, the current diversified development of domestic pharmaceutical equipment companies is mainly reflected in the adjustment of product lines, the extension of the industrial chain, and the improvement of services .
-
Junshi Biotech's second new crown neutralizing antibody was approved to enter clinical trials
Time of Update: 2021-12-05
Recently, Junshi Biotech announced that the clinical trial application for JS026 injection has been approved by the Food and Drug Administration for the prevention and treatment of new coronavirus pneumonia (COVID-19) .
-
5 tables to master: the clinical application of 48 kinds of drugs for insomnia, anxiety and depression
Time of Update: 2021-10-20
in this class of drugs have a better effect on patients with insomnia and anxiety, and can reduce the frequency of night awakening, but Can significantly reduce slow-wave sleep, leading to a decline in recovery after sleep .
-
The old drug "Ivermectin" discovered in 1975 may become a "game changer" in the fight against cancer
Time of Update: 2021-09-13
Checkpoint inhibitors are a class of drugs that help the human immune system detect and eradicate cancer cells .
Although the results are still in the preliminary stages, Mountain Valley believes that their new drug Ivectosol may be a "true game changer" in cancer treatment .
